Latest Ramucirumab Stories
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept.
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S.
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
DALLAS, February 21, 2014 /PRNewswire/ -- RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as
MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions
This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer.
New research study “Gastric Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020” prepared by GlobalData has been recently published by Market Publishers